Induced pluripotent stem cells without viral vectors
This article was originally published in Scrip
Executive Summary
The Japanese team which generated induced pluripotent stem (iPS) cells from normal human skin cells last year has developed a new virus-free technique. Professor Shinya Yamanaka and others at Kyoto University successfully transfected mouse embryonic fibroblasts with the requisite genes using plasmids rather than retroviral or lentiviral vectors. These can become integrated into the genome, increasing the risk of cancer. The technique so far has a lower production efficiency and has not been applied to somatic cells. iPS cells behave like embryo-derived stem cells but with none of the ethical and immunogenicity concerns, and may in future be used in novel regenerative therapies.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.